Hamburg ots - Ein Pressesprecher verdient in Deutschland im Durchschnitt monatlich 4. Die zweite Folge "Hochzeit auf den ersten The study, which was completed in September, investigates the efficacy and safety of
Telaprevir prescribing information fdating twice-daily dosing BID of telaprevir versus dosing every eight hours q8h in people chronically infected with genotype-1 hepatitis C virus HCV who had not been previously treated.
These data offers hope for yet further improvements to treatment regimens, with no compromise on rates. The results demonstrated that BID dosing of telaprevir 1,mg in combination with peginterferon alfa and ribavirin PRachieved similar cure rates, also known as sustained virological response SVR12 to q8h dosing of telaprevir mg The most common adverse events experienced were fatigue, pruritus, anemia, nausea and rash.
At 12 weeks, telaprevir treatment ended and patients continued on PR alone for up to week 24 or week 48 depending on their viral response at week 4. Patients were followed up for a further 12 weeks to monitor cure rates SVR Unlike previous treatments, DAAs act directly on viral enzymes and prevent the virus from replicating.
Janssen has rights to commercialize telaprevir in Europe, South America, Australia, the Middle East and certain other countries. Please see full Summary of Product Characteristics or visit http: In clinical trials, the incidence of adverse events of at least moderate intensity was higher in the telaprevir group than in placebo group both groups receiving peginterferon alfa and ribavirin. The most frequently reported adverse reactions incidence greater than or equal to 5.
Severe rashes were reported with telaprevir combination treatment Telaprevir prescribing information fdating 4. Rash led to discontinuation of telaprevir alone in 5. Hemoglobin values of HCV is a blood-borne infectious disease that affects the liver. At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases.